Assessment of PENG Block as a Part of Multimodal Analgesia Following Hip Surgeries.

NCT06916000 | Active Not Recruiting

• 1 other identifier: FMASU MS428/2024
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

to study the effect of Pericapsular nerve group (PENG) block as a part of multimodal analgesia regimen for hip arthroplasties

Conditions

Anesthesia

Outcome Measures

Primary Outcomes (1)

• Pain score: pain assessment using a Numeric Rating System (NRS) immediately in the postoperative period.

  Pain score: pain intensity will be evaluated using a Numeric Rating System (NRS) immediately in the postoperative period, every 2 hours during the first 6 hours and then every 6 hours till 24 hours postoperatively. Scores ranging from 0 to 10, with 0 indicating the absence of pain and 10 indicating the worst possible pain.

  24 hours

Secondary Outcomes (1)

• Rescue analgesia timing and opioid consumption over 24 hours

  24 hours

Study Arms (2)

PENG block group (25 particiants)

ACTIVE COMPARATOR

For postoperative pain management, all patients of this arm will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango. In addition, multimodal analgesia will be given including IV paracetamol 1000 mg BID and oral celecoxib tablet 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as demand dose and when the NRS pain score was equal to or greater than 4 points.

Drug: Pericapsular nerve group (PENG) block

Group C: control group (25 participants)

EXPERIMENTAL

Patients will receive only other multimodal analgesics

Other: Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.

Interventions

Pericapsular nerve group (PENG) block DRUG

As a part of multimodal analgesia patients will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango. All patients will receive the same analgesic protocol, which included IV paracetamol 1000 mg BID and NSAIDs if no contra-indication; PO celecoxib 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as bolus demand dose and when the NRS pain score was equal to or greater than 4 points.

PENG block group (25 particiants)

Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine. OTHER

Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.

Group C: control group (25 participants)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age group: 18 years and older.
• ASA classification I to III.
• BMI : 18-35 .
• Gender: both sex

You may not qualify if:

• Patient refusal.
• Patients on long-term pain medications.
• History of allergic reactions to local anesthetics
• Patients who had mental illness or uncooperative patients.
• BMI \> 35 .
• Patients having coagulopathies or on anticoagulant or antiplatelet therapy.
• Severe cardiopulmonary disease
• ASA IV or more
• Diabetic or other neuropathies

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Faculty of medicine, Ain Shams University

Abbasia, Cairo Governorate, 11517, Egypt

Location

MeSH Terms

Interventions

Dental Occlusion; Bupivacaine

Intervention Hierarchy (Ancestors)

Dentistry; Dental Physiological Phenomena; Digestive System and Oral Physiological Phenomena; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 28, 2024
• First Posted: April 8, 2025
• Study Start: June 27, 2024
• Primary Completion: June 1, 2025
• Study Completion: June 1, 2025
• Last Updated: April 8, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)